A Study to Learn About the Study Medicine Called PF-07799933 in People With Advanced Solid Tumors.
Melanoma, Colorectal Cancer, Non-Small-Cell Lung Cancer
About this trial
This is an interventional treatment trial for Melanoma
Eligibility Criteria
This study is seeking participants who meet the following eligibility criteria:
Inclusion Criteria:
- Diagnosis of advanced/metastatic solid tumor including primary brain tumor.
- Qualifying BRAF alteration (V600 or non-V600 Class II/Class III BRAF alteration), in tumor tissue and/or blood (ie circulating tumor deoxyribonucleic acid [DNA], or ctDNA).
- Disease progressed during/following last prior treatment and no satisfactory alternative treatment options (Part 1 and Part 2).
- Tumor specific cohorts (melanoma, colorectal cancer) must have received specific prior approved therapies
Exclusion Criteria:
- Brain metastasis larger than 4 cm
- Systemic anti-cancer therapy or small molecule therapeutics ongoing at the start of study treatment.
- For participants who may get binimetinib on study, history or current evidence of retinal vein occlusion (RVO) or concurrent neuromuscular disorder associated with elevated creatine kinase (CK)
Sites / Locations
- Highlands Oncology GroupRecruiting
- Highlands Oncology GroupRecruiting
- Highlands Oncology GroupRecruiting
- Clinical And Translational Research CenterRecruiting
- UCHealth Sue Anschutz-Rodgers Eye CenterRecruiting
- University of Colorado Anschutz Medical CampusRecruiting
- University of Colorado Hospital - Anschutz Cancer Pavilion (ACP)Recruiting
- University of Colorado Hospital - Anschutz Inpatient Pavilion (AIP)Recruiting
- University of Colorado Hospital - Anschutz Outpatient Pavilion (AOP)Recruiting
- University of Miami Hospital and Clinics, Sylvester Cancer Center
- Brigham and Women's HospitalRecruiting
- Dana-Farber Cancer InstituteRecruiting
- DFCI Chestnut HillRecruiting
- Brigitte Harris Cancer PavilionRecruiting
- Henry Ford HospitalRecruiting
- Henry Ford Medical Center - ColumbusRecruiting
- MSK David H. Koch Center for Cancer CareRecruiting
- Memorial Sloan Kettering Cancer Center 53rd streetRecruiting
- Memorial Sloan Kettering Cancer CenterRecruiting
- Providence Cancer Institute Franz ClinicRecruiting
- Providence Portland Medical CenterRecruiting
- Sarah Cannon Research Institute - PharmacyRecruiting
- Tennessee Oncology PLLCRecruiting
- Tennessee Oncology, PLLCRecruiting
- TriStar Bone Marrow TransplantRecruiting
- TriStar Centennial Medical Center - Cell Processing LabRecruiting
- TriStar Centennial Medical centerRecruiting
- South Texas Accelerated Research Therapeutics (START)Recruiting
- Cross Cancer Institute
- The Ottawa Hospital - General CampusRecruiting
- Princess Margaret Cancer Centre
- McGill University Health CentreRecruiting
- Rabin Medical Center
- Sourasky Medical Center
- Hadassah Medical Center
Arms of the Study
Arm 1
Arm 2
Arm 3
Arm 4
Arm 5
Arm 6
Arm 7
Arm 8
Experimental
Experimental
Experimental
Experimental
Experimental
Experimental
Experimental
Experimental
Monotherapy dose escalation (Part 1)
Combination dose escalation (Part 2)
Dose expansion (Part 3) - Tumor and mutation specific Cohort 1
Dose expansion (Part 3) - Tumor and mutation specific Cohort 2
Dose expansion (Part 3) - Tumor and mutation specific Cohort 3
Dose expansion (Part 3) - Tumor and mutation specific Cohort 4
Dose expansion (Part 3) - Tumor and mutation specific Cohort 5
Dose expansion (Part 3) - Basket Cohort 6
Participants will receive PF-07799933
Participants will receive PF-07799933 in combination with binimetinib or cetuximab
Participants will receive PF-07799933
Participants will receive PF-07799933 in combination with binimetinib
Participants will receive PF-07799933
Participants will receive PF-07799933 in combination with cetuximab
Participants will receive PF-07799933 in combination with cetuximab
Participants will receive PF-07799933 in combination with binimetinib or cetuximab